Bolt Biotherapeutics

Bolt Biotherapeutics

  • Founded: 2015
  • Location: Redwood City, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Breast cancer
  • Drug types: ONC
  • Lead product: BDC-1001
  • Product link:
  • Funding: $264M IPO Feb 2021; $93.5M C Jul 2020; $54M B Feb 2019
  • Investors: Pivotal bioVenture Partners, Nan Fung Life Sciences

job board

Short description:

Systemically delivered Immune-Stimulating Antibody Conjugates

Drug notes:

Also Clin1 multiple cancers; BDC-3042 Clin0 solid tumors; 4 undisclosed programs RD solid tumors, undisclosed

Long description:

Bolt Biotherapeutics is developing immuno-oncology therapies to eliminate tumors. Many tumors create an immune-suppressive environment to prevent their clearance. Bolt is leveraging the precision of antibody targeting to activate both the immune response in the tumor microenvironment. By identifying immune-stimulating antibody conjugates (ISACs), which Bolt refers to as Boltbody, a localized anti-tumor immune cascade can be stimulated to offer personalized therapeutic options. Using this approach, Bolt can address difficult-to-treat solid tumors and generate long-term anti-tumor responses through immunological memory. Bolt’s lead candidate, BDC-1001, is a HER2 BoltBody ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy